E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better.
*Subjects must be 18 years of age or older.
*All subjects must have disease that is completely surgically resected.
* All subjects must be deemed disease free at the time of study entry.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Up to 15 years
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com